scholarly journals An 8-week, double-blind, placebo-controled, multicenter, Ambulatory Blood Pressure Monitoring (ABPM) study of Teveten (Eprosartan Mesylate) 600mg and 1200mg QD in patients with essential hypertension

2005 ◽  
Vol 18 (5) ◽  
pp. A93-A93 ◽  
Author(s):  
H PUNZI ◽  
C PUNZI
Sign in / Sign up

Export Citation Format

Share Document